

REMARKS

I. Overview

Claims 1-27, 32-39 are pending in the instant application. The Examiner has stated that claims 1-7, 14-18, and 20-21 are allowable. Claims 8-13, 19, 22-27 and 32-29 have been cancelled. A new Sequence Listing has been submitted and the Specification amended according to the Examiner's suggestion. Passage to issuance is therefore respectfully requested.

II. Rejections Under 35 U.S.C. § 112, first paragraph

Claims 8-13, 22-27, and 32-39 stand rejected under 35 U.S.C. § 112, first paragraph, because the specification, while being enabling for practicing the claimed invention *in vitro*, does not reasonably provide enablement for practicing the full scope of the claimed invention *in vivo*. Claims 8-13, 22-27, and 32-39 have been cancelled rendering this rejection moot.

III. Double Patenting

Claim 19 stands rejected under 35 U.S.C. § 101 as claiming the same invention as that of claim 18 of prior U. S. Patent No. 6,309,830 B1. Claim 19 has been cancelled rendering this rejection moot.

IV. Specification/Sequence Rules

The Examiner writes that the description of Figure 2A does not include a sequence identifier for the tRNA structure set forth in this figure, nor does the Sequence Listing include a sequence identifier which corresponds to this structure, although SEQ ID NO:14 discloses the mutated form of the tRNA structure. Accordingly, Applicants have added the sequence identified in Figure 2A to the Sequence Listing, so that the sequence is now listed as SEQ ID

NO: 17. Applicants have also amended the description of Figure 2A so that it now recites the SEQ ID NO:17.

Figure 10 discloses 4 nucleotide sequences, and the description of this figure recites (SEQ ID NOS:5-8). However, the Examiner writes that the correct sequences should be SEQ ID NOS:7-10. The Examiner writes that the description of Figure 11 makes reference to SEQ ID NO:9, however the description should be amended to recite SEQ ID NO:11. The Examiner writes that the description of Figure 12 should be modified by replacing SEQ ID NO:10 with SEQ ID NO:12. The Examiner writes that the description of Figure 13 should be modified by replacing SEQ ID NO:11 with SEQ ID NO:13. The Examiner writes that the description of Figure 14 should be modified by replacing SEQ ID NO:10 with SEQ ID NO:14.


Applicants thank the Examiner for pointing out these inadvertent errors and have accordingly amended the descriptions of Figures 10-14 so that they now recite SEQ ID NOS:7-10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14 respectively.

V. Conclusion

No fees or extensions of time are believed to be due in connection with this amendment; however, consider this a request for any extension inadvertently omitted, and charge any additional fees to Deposit Account No. 26-0084.

Reconsideration and allowance is respectfully requested.

Respectfully submitted,

A handwritten signature in black ink, reading "Janae E. Lehman Bell". The signature is fluid and cursive, with the first name "Janae" being the most prominent.

JANAÉ E. LEHMAN BELL, PH.D., Reg. No. 55,370
McKEE, VOORHEES & SEASE, P.L.C.

801 Grand Avenue, Suite 3200

Des Moines, Iowa 50309-2721

Phone No: (515) 288-3667

Fax No: (515) 288-1338

CUSTOMER NO: 22885

Attorneys of Record

- pw -